There were numerous articles in June 2018 that covered a wide range of topical issues. Here are five of the best stories you might have missed… (Click the headline to finish reading the story)
The utilization of machine learning in the design, conduct and interpretation of clinical trials has been eagerly anticipated. Machine learning has the potential to increase the efficiency of almost every aspect of medical research from identifying appropriate patients to optimizing strategies to send study supplies to clinical sites. The advent of electronic tools to medical research parallels the expectation of precision medicine for patients, improving benefit while reducing risk.
The persistent lack of diversity among clinical trial participants, and the resulting lack of data on multi-ethnic patient bases, requires us to consider the implications of this situation before we can address possible solutions.
It may seem obvious, but it is worth stating: when segments of the population are not included in clinical trials at levels that do not meet statistical significance, it is impossible to determine if the therapy in question will work equally, better, or worse as for the population in which it is studied.
Clinical supply management is facing a number of challenges in a rapidly changing environment which necessitates constant adjustments. Innovations enable the clinical supply chain to brace for upcoming challenges.
In pharmaceutical and clinical development, the customer and the sponsor have different views on innovation and improvement. However, there are also aspects which are of utmost importance for both parties, such as patient safety, study adherence, compliance, and others.
“All CROs are the same,” my CMO said to me shortly after I joined a new pharma company. “They all say great things but you can’t count on them to deliver. I wish we still had our own study teams filled with CRAs and assistants and…” – his voice trailed off wistfully as he remembered the glory days of clinical operations departments well-stocked with fully trained staff delivering concierge site management services. I remember those days too and I sympathize, but as we all know, clinical trial management has left that era some time ago, and in its place most pharma and biotech companies have trimmed down our in-house resources to become increasingly dependent upon the services of external resource providers, such as full-service CROs, with varying degrees of success.
In 2017, Clinical Trials Arena conducted its first ever salary survey, with the aim of gauging the current state of the life sciences jobs market. Over 200 industry professionals took part in the study, all of whom were attendees of Arena International’s global series of clinical events. Insight from respondents across the world allowed CTA to glean where professions in the life sciences are heading, as well as what individuals look for in both their current roles and when they seek new challenges.
We would like to take this opportunity to extend our deepest thanks to all those who participated in our survey. It is one of the only salary surveys specific to the life sciences industry that looks to provide invaluable data for both hiring managers and industry professionals. The survey opens the door to greater salary transparency, providing a snapshot of what you can expect to earn relative to your skills, experience and location. The results illustrate and confirm the ongoing growth and success of careers within the life sciences industry.
In case you missed Supply Chain Week last month, click here to read exclusive articles delving into the current issues and concerns involving oncology trials.
PHOTO CREDIT: Rob Nguyen